Fatty liver diseases, comprising alcoholic fatty liver disease and non-alcoholic fatty liver disease, are the most common chronic liver diseases all over the world. Therefore, there is an urgent need to investigate effective therapies for fatty liver disease.
Various theories have been proposed to explain the pathogenesis of fatty liver, but one of the most common abnormalities is the alteration of gut-liver axis. Mounting evidence suggests that supplementation of probiotics and postbiotics can modulate the elements of gut-liver axis, particularly gut microbiota. Probiotics are the “live microorganisms that, when administered in adequate amounts, confer a health benefit on the host”, and postbiotics are defined as the “preparation of inanimate microorganisms and/or their components that confers a health benefit on the host”. Studies have revealed that probiotics could inhibit the growth of intestinal pathogens by producing inhibitory antimicrobials that competitively adhere to the mucosa and epithelium. Besides, postbiotics could strengthen the epithelial barrier integrity via mucin and defensins, and modulate local and systemic immune responses of the host. In addition, probiotics or postbiotics could improve the production of intestinal short chain fatty acids (SCFAs), including the most prominent ones, acetate, propionate, and butyrate. SCFAs can act directly as lipid precursors in hepatic metabolic processes and also regulate molecular signaling by acting as ligands for G-protein coupled receptors (GPRs) that mediate signal transduction, which plays an important role in controlling the development of NAFLD.
This research topic aims to cover the use of probiotics or postbiotics to improve the management of fatty liver disease in humans and provide a platform to discuss the understanding of the gut-liver crosstalk and its implications for microbe-based treatment approaches. In addition, it is important to note that, this Research Topic aims to collect publications relevant to HUMAN NUTRITION ONLY. Studies on farm animals other than animal models for human nutrition will not be accepted in this Research Topic and will be re-directed to other relevant Frontiers journals.
We welcome submissions including, but not limited to, the following topics:
• Analyze the protective effects of probiotics and postbiotics against fatty liver disease;
• Explore the protective mechanisms of probiotics and postbiotics from the aspects of glucose metabolism, lipid metabolism, inflammatory stress, apoptosis, gut microbiota, transcriptomics, proteomics, metabolomics, etc.;
• Explore the synergic effects of probiotics and postbiotics on host health and nutrition.
Fatty liver diseases, comprising alcoholic fatty liver disease and non-alcoholic fatty liver disease, are the most common chronic liver diseases all over the world. Therefore, there is an urgent need to investigate effective therapies for fatty liver disease.
Various theories have been proposed to explain the pathogenesis of fatty liver, but one of the most common abnormalities is the alteration of gut-liver axis. Mounting evidence suggests that supplementation of probiotics and postbiotics can modulate the elements of gut-liver axis, particularly gut microbiota. Probiotics are the “live microorganisms that, when administered in adequate amounts, confer a health benefit on the host”, and postbiotics are defined as the “preparation of inanimate microorganisms and/or their components that confers a health benefit on the host”. Studies have revealed that probiotics could inhibit the growth of intestinal pathogens by producing inhibitory antimicrobials that competitively adhere to the mucosa and epithelium. Besides, postbiotics could strengthen the epithelial barrier integrity via mucin and defensins, and modulate local and systemic immune responses of the host. In addition, probiotics or postbiotics could improve the production of intestinal short chain fatty acids (SCFAs), including the most prominent ones, acetate, propionate, and butyrate. SCFAs can act directly as lipid precursors in hepatic metabolic processes and also regulate molecular signaling by acting as ligands for G-protein coupled receptors (GPRs) that mediate signal transduction, which plays an important role in controlling the development of NAFLD.
This research topic aims to cover the use of probiotics or postbiotics to improve the management of fatty liver disease in humans and provide a platform to discuss the understanding of the gut-liver crosstalk and its implications for microbe-based treatment approaches. In addition, it is important to note that, this Research Topic aims to collect publications relevant to HUMAN NUTRITION ONLY. Studies on farm animals other than animal models for human nutrition will not be accepted in this Research Topic and will be re-directed to other relevant Frontiers journals.
We welcome submissions including, but not limited to, the following topics:
• Analyze the protective effects of probiotics and postbiotics against fatty liver disease;
• Explore the protective mechanisms of probiotics and postbiotics from the aspects of glucose metabolism, lipid metabolism, inflammatory stress, apoptosis, gut microbiota, transcriptomics, proteomics, metabolomics, etc.;
• Explore the synergic effects of probiotics and postbiotics on host health and nutrition.
